Answers are grounded in this paper and cite their sources.
The development of neutralizing factor VIII (FVIII) inhibitors remains a major therapeutic challenge in severe hemophilia A. We report 2 patients with complex inhibitor histories who achieved rapid, sustained inhibitor eradication with efanesoctocog alfa. Immune tolerance induction was initiated at 100 U/kg 3 times weekly, with subsequent dose reduction after inhibitor clearance. Inhibitor titers declined to undetectable levels (<0.5 Bethesda Units) within 6 weeks in one case and 3 months in the other, with FVIII recovery exceeding 90%. Transition to once-weekly individualized prophylaxis maintained functional FVIII activity and therapeutic FVIII trough levels (4%-6%), allowing discontinuation of emicizumab. Sustained bleed-free outcomes were achieved with individualized prophylactic dosing without inhibitor recurrence. These cases support efanesoctocog alfa-based immune tolerance induction as a promising strategy for rescue and retreatment in patients with complex inhibitor histories.
No takes yet. Share an insight, caveat, or question.
Ashraf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: